डॉ डैटसन लैब्स

बीएसई: 533412  |  NSE: DRDATSONS  |  ISIN: INE928K01013  |  Pharmaceuticals

खोजें डॉ डैटसन लैब्स कनेक्शन
अध्यक्षीय भाषण साल : Mar '12
Dear Shareholder''s
 The fiscal 2011-12 was a significant year for Aanjaneya Life care for
 its robust performance on the one hand and diversity of initiatives to
 accelerate this growth on the other.
 The financial year under review commenced on a strong note. Our
 Rs.117-crore IPO was oversubscribed 1.11 times (retail investors 1.84
 times and non- institutional investors 2.65 times) despite a
 challenging investor environment.
 Aanjaneya justified the faith reposed by its shareholders through its
 first-ever performance following listing. The Company grew its top line
 50%, EBIDTA 52% and profit after tax 14% even as most companies were
 affected by the economic slowdown.
 Our products received increasing acceptance in the global and domestic
 markets. Our quinine-based APIs, our flagship business vertical,
 registered a robust 52.46% growth in sales volumes; our formulations
 business grew 46.69% as we strengthened the visibility of our generic
 brands. In our services space, we added reputed names to our P- 2-P
 clients. The combination of these initiatives translated into stronger
 margins, liquidity and brand.
 The result was increasing peer recognition. Aanjaneya was nominated
 Emerging Company of The Year 2011 and India''s Most Technically &
 Scientifically Advanced Pharmaceutical Manufacturing Unit of the Year
 2011 at 4th Annual Pharmaceutical Leadership Summit & Awards 2011.
 The journey has just begun
 At Aanjaneya, we are convinced that we will successfully enhance value
 for our shareholders through an ability to significantly increase
 volumes and value.
 Volumes: At Aanjaneya, we are convinced that in a challenging and
 fast-evolving industry space, success is derived from the ability to
 engage in successful Greenfield or brown field projects. In 2011-12,
 Aanjaneya acquired Apex Drugs and Intermediates Ltd, a Hyderabad-based
 integrated API company for Rs.250 crore. The acquisition helped the
 Company achieve in weeks what would normally have taken three years to
 accomplish. This acquisition immediately added a number of APIs in new
 therapeutic segments (AIDS-HIV, diabetes, Ace inhibitors and CNS).
 Besides, this acquisition is expected to add about Rs.200 crore to our
 top line without stretching our financials.
 Aanjaneya reinforced this acquisition through the following
 - Two GMP-compliant API blocks are expected to commence operations in
 September 2012, adding 10 new APIs to the product basket.
 - One intermediate block has commenced operations in March 2012 - it
 manufactures one API in addition to intermediates for the new API
 - The full benefit of the Apex acquisition will add to the top line.
 - The new 50-million unit table ting plant will commence operations in
 September, 2012.
 - The EU-GMP lozenge unit will commence operations in September,
 Value: At Aanjaneya, we are convinced that the higher the margins, the
 stronger the cash flow, the lower the debt, the stronger the ability to
 negotiate and the relatively simpler way to enhance shareholder value.
 At our Company, we are engaging in a significant initiative to enhance
 value: extending our formulations basket to lozenges is one of the most
 important. We are developing lozenges as Ethical Prescription Dosages
 (EPD) across multiple therapeutic segments, a pioneering initiative
 within the Indian pharmaceutical industry.
 Lozenges use the sublingual route (through the mouth) to enter the
 bloodstream with a nominal reaction time of only 10-12 minutes as
 against most tablets or capsules, which disintegrate only in the
 intestine with a reaction time of 35-45 minutes. We are optimistic that
 this product superiority will lead to stronger prescription compliance
 and consumer pull; for instance, the US lozenge market is estimated at
 US$ 10 billion while the Indian lozenge market is only Rs.1,000 crore, a
 difference that is expected to narrow. The Company entered this space
 following the acquisition of Prophyla in 2010, emerging among five
 lozenge manufacturers in India.
 Going ahead, the Company will produce lozenges that address basic
 health issues, widening their relevance. In line with this objective,
 the Company created a dedicated R&D team to develop lozenges as a
 pharmaceutical product, reconciling allopathic and ayurvedic benefits.
 The Company created a large basket of unique lozenges of which 80% can
 be provided to OTC consumers. The Company developed a bouquet of
 first-time products with ayurvedic active ingredients in multiple
 The Company is reinforcing its existing capacity (2.5 million lozenges
 a day) with a completely new lozenge block 40 million capacity) in
 compliance with EUGMP guidelines to be commissioned in 2012- 13. The
 Company is collaborating with a marketing company with a strong
 pan-India presence to market its lozenges. It filed dossiers to
 register lozenges in 15 countries and received registrations from some.
 Besides, the Company expects to enhance value through the following
 - We launched Artemisinin products - third-generation anti- malaria
 therapy and other niche APIs at its new GMP blocks - quinine sells for
 Rs.6,000 a kg and Artemisinin- based salts is at Rs.50,000 a kg; an
 estimated 40% the Artemisinin volume will further be value-added into
 - We expect to consume a larger proportion of APIs from the Mahad
 unit at our new table ting facility following commissioning.
 - We expect to convert about 30% of the APIs from this unit into
 formulations at our Pune unit (new table ting block to be commissioned
 in September 2012); formulation sales are expected to be four times our
 API sales.
 - We will convert small quinine volumes into quinine lozenges.
 Message to shareholders
 We are at an inflection point in our history where growth in revenues,
 margins and profits will translate into enhanced value in the hands of
 our shareholders.
 Warm regards,
 Dr Kannan Vishwanath
स्रोत: रेलीगरे टेचनोवा

न्यूज़ फ़्लैश

  • MARKET CUES : FIIs ने कैश में `664 Cr की खरीदारी की
  • MARKET CUES : DIIs ने कैश में `245 Cr की बिकवाली की
  • MARKET CUES : FIIs ने F&O में `497 Cr की खरीदारी की
  • MARKET CUES : इंडेक्स फ्यूचर्स में `491 Cr की बिकवाली की
  • MARKET CUES : इंडेक्स ऑप्शंस में `1203 Cr की खरीदारी की
  • MARKET CUES : स्टॉक फ्यूचर्स में `141 Cr की बिकवाली की
  • JEFFERIES ON MGL : BUY रेटिंग, लक्ष्य घटाकर `1180/Sh
  • CITI ON NMDC : BUY रेटिंग, लक्ष्य `125/Sh
  • MS ON ADANI PORTS : Overweight रेटिंग, लक्ष्य `408/Sh
  • CITI ON COAL INDIA : BUY रेटिंग, लक्ष्य बढ़ाकर `270/Sh

अभी देखें

सौदा आपका




(August 06, 2018)

AT (Rs)






Super Combo

Powerful mix of both trader and investor packs with timely expert advice.


Designed especially for traders looking to tap the profit opportunities of volatile markets.


For all investors looking to unearth stocks that are poised to move.